P

Pfizer

Makes cancer drugs, vaccines and other medicines

Principal Scientist - Materials Science

Full-TimeUpdated
$106k - $176.6k/yr+ 15% target bonus + Share-based long-term incentive program
Senior
Master's, PhD
Groton, CT, USA
In PersonOn-premise in Groton, Connecticut.
Biology & BiotechBioprocess & Biomanufacturing
No H1B Sponsorship

About the job

Requirements
  • A Ph.D. in Chemistry, Engineering, Materials Science, Pharmaceutics, or a related field, with at least five years of relevant materials science experience in industry; or a relevant master's degree with at least ten years of relevant materials science experience.
  • Experience in small-molecule crystallization and solid-state characterization, including techniques such as X-ray powder diffraction, polarized light microscopy, infrared or Raman spectroscopy, laser diffraction, differential scanning calorimetry, thermogravimetric analysis, and nuclear magnetic resonance.
  • Experience with regulatory submissions and query responses related to solid form and particle characterization.
  • Strong data analysis skills and knowledge of statistical concepts.
  • A strong interest and motivation to learn new technologies and concepts.
  • Strong oral and written communication skills.
Responsibilities
  • Investigate the solid-form and particle properties of drug molecules ranging from small molecules to Beyond Rule of 5 candidates and peptides.
  • Generate solid-state chemistry and particle-characterization data using instrumentation and computer models, and interpret the data to support bringing new medicines to market.
  • Serve on multidisciplinary project teams and define the final drug-substance form, such as salt, polymorph, or hydrate, and the physical attributes needed for optimum active pharmaceutical ingredient, drug product intermediate, and drug product performance.
  • Participate on multidisciplinary project teams as the Materials Science Lead, advancing molecules from Discovery to drug product launch by leading a matrix team of Materials Science colleagues to define and implement solid-form and particle-design and characterization strategies according to project timelines.
  • Influence formulation design and drug-product process development by integrating physical and surface characterization data for active pharmaceutical ingredient and drug-product-intermediate powders.
  • Crystallize and screen neutral molecules, salts, and co-crystal forms of drug candidates, including hydrates, solvates, and polymorphs, and evaluate their acceptability as drug substances for chemical manufacturing and pharmaceutical formulation.
  • Conduct solid-state physical and chemical characterization of small molecules of pharmaceutical relevance, including particle characterization such as particle size and shape, and solid-state characterization such as spectroscopy, single-crystal X-ray diffraction, electron diffraction, X-ray powder diffraction, and thermal analysis.
  • Apply computational approaches to design experiments and predict the solid form, particle crystalline properties, and performance of drug-substance and drug-product-intermediate samples.
  • Oversee external partners conducting laboratory studies and provide tactical guidance and critical analysis of raw data.
  • Coach and mentor laboratory scientists in the design, execution, and analysis of materials-science data.
  • Solve scientific problems using contemporary materials-science experimental and computational techniques.
  • Draft and review sections of regulatory submissions and query responses, and deliver reports supporting patenting of Pfizer intellectual property.
  • Provide materials-science support to colleagues in other departments and collaborate with project teams to define drug-development strategy.
  • Lead development of new scientific approaches and knowledge within the global Materials Science organization and with key academic collaborators.
Desired Qualifications
  • Experience using contemporary computational approaches to predict the properties and performance of pharmaceutical materials, including tools such as HABIT, Materials Studio, Mercury, CosmoTherm, and SimCU to predict powder-sample properties and performance.
  • Experience curating data to support development of predictive tools.
  • Experience in powder characterization, such as polarized light microscopy, electron microscopy, image analysis, and laser diffraction, and surface-property testing, such as inverse gas chromatography, energy-dispersive X-ray spectroscopy, and atomic force microscopy, for fine powders.
  • Understanding of the physical and chemical properties needed for drug-substance and drug-product-intermediate manufacture and their impact on successful formulation into drug product.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 27th, 2026
AT&T, Pfizer and Zoetis offer yields up to 5.8% with shares under $100

Rising interest rates and bond yields have made dividend stocks less appealing, pushing many lower and their yields higher. Three that trade below $100 are AT&T, Pfizer, and Zoetis, according to The Motley Fool. AT&T trades around $21, down about 16% this year, with a price-to-earnings (P/E) multiple of 11 against 23 for the S&P 500. It yields 5.3% after revenue grew more than 5% in the September quarter. Pfizer trades near $30 and yields 5.8%. Its forward P/E is 10, though its shares are down more than 30% over five years. Zoetis, down 37% this year, trades below $80 with a P/E of 13 and a yield of about 2.6%. Its payout ratio is around 34% of earnings, and it has 12 potential blockbusters in its pipeline.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.